China Approves Clinical Trial of Omicron Vaccine

By Lars James Hamer, April 28, 2022

0 0

A Chinese vaccination for the Omicron variant of COVID-19 has been approved for clinical trials, reports CGTN.

The vaccine was developed by the China National Biotec Group (which has affiliations with Sinopharm) and was approved by the National Medical Products Administration on Tuesday, April 26. 

Preliminary tests – such as safety evaluations in animals and immunogenicity research – showed that the vaccine is capable of producing antibodies that can fight off COVID variants, including Omicron. 

China National Biotec Group have previously developed COVID-19 vaccines in the country and conducted research into its many variants, including Beta and Delta. 

The trial will be carried out on adults aged 18 and above who have been inoculated with two or three doses of a COVID-19 vaccine.

[Cover image via Flickr]

more news

China Halts Visas for South Koreans & Japanese Over COVID Rules

The measures are in effect, as of press time.

Where To Get a COVID Test for International Travel in Guangzhou

A handy list of hospitals that offer English COVID test results.

Ending 0-COVID: Beijing Subway to Stop Temperature Checks

Temperature checks have been standard procedure since early 2020 when COVID-19 first broke out in China.

COVID-19 Forces Shanghai Schools Online

Schools closed until further notice.

Home Quarantine in Beijing for COVID Cases – What We Know So Far

Numerous reports have emerged of positive cases being allowed to undergo home quarantine in Beijing.

0 User Comments

In Case You Missed It…

We're on WeChat!

Scan our QR Code at right or follow us at thatsonline for events, guides, giveaways and much more!

7 Days in China With

Weekly updates to your email inbox every Wednesday

Download previous issues

Never miss an issue of That's Magazines!

Visit the archives